Chemical compounds

Chlorobenzene Market 2020-2024 | Increased Demand for Chlorobenzene from the Chemical Industry to Boost Market Growth | Technavio

Saturday, June 6, 2020 - 1:00am
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200605005395/en/
    Technavio has announced its latest market research report titled Global Chlorobenzene Market 2020-2024 (Graphic: Business Wire)
    Chlorobenzene and its by-products are some of the most consumed materials in the chemical industry.
  • Many such applications are increasing the consumption of chlorobenzene in the chemical industry, which is driving the growth of the market.
  • The market is witnessing an increase in the demand for chlorobenzene from emerging economies such as China, India, and Japan.
  • In addition, the increasing demand for personal care products, chemicals, and pharmaceuticals in APAC is significantly contributing to the overall growth of the global chlorobenzene market.

Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of Tyvaso Patents

Friday, June 5, 2020 - 8:30pm

9,604,901 (901) and 9,593,066 (066) relating to UTCs Tyvaso, a nebulized treprostinil solution for the treatment of pulmonary arterial hypertension (PAH).

Key Points: 
  • 9,604,901 (901) and 9,593,066 (066) relating to UTCs Tyvaso, a nebulized treprostinil solution for the treatment of pulmonary arterial hypertension (PAH).
  • The LIQ861 NDA was filed under the 505(b)(2) regulatory pathway with Tyvaso as the reference listed drug.
  • Both the 066 patent and the 901 patent are continuation patents of U.S. Patent No.
  • The Company believes it is positioned well for a favorable outcome in the IPR processes invalidating the 066 and 901 patents.

Poll: 78% of Americans Aren't Prepared for a Disaster When it Comes to Food and Water

Friday, June 5, 2020 - 3:42pm

New national polling, commissioned by DisasterChecklist.org and conducted by Engine Group, shines a light on America's lack of preparedness.

Key Points: 
  • New national polling, commissioned by DisasterChecklist.org and conducted by Engine Group, shines a light on America's lack of preparedness.
  • When asked about the items believed to be most important during emergencies, 71 percent of respondents said canned food and 70 percent said bottled water.
  • Between canned goods and bottled water, the latter was sought out more, with 61 percent of all respondents reporting they purchased water.
  • "Having enough bottled water and non-perishable food on hand for your family should be a priority for everyone."

$2+ Billion Global Reusable Water Bottles Industry (2019 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com

Friday, June 5, 2020 - 1:53pm

The "Reusable Water Bottles - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Reusable Water Bottles - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis and the looming economic recession, the Reusable Water Bottles market worldwide will grow by a projected US$1.4 Billion, during the analysis period, driven by a revised compounded annual growth rate (CAGR) of 2.2%.
  • The global analysis and forecast periods covered within the report are 2020-2027 (Current & Future Analysis) and 2012-2019 (Historic Review).
  • An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry.

Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress

Friday, June 5, 2020 - 12:05pm

Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that new subgroup analyses from the completed AURORA pivotal trial of voclosporin were presented.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that new subgroup analyses from the completed AURORA pivotal trial of voclosporin were presented.
  • The presented data demonstrated clinically meaningful benefits of voclosporin for trial participants across ethnicities and self-reported race.
  • Furthermore, all other pre-specified subgroup analyses (age, sex, race, biopsy class, region, and prior mycophenolate mofetil use) favored voclosporin.
  • Overall mortality in the trial was low, with six deaths observed; one in the voclosporin arm and five in the control group.

Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma

Friday, June 5, 2020 - 8:22am

Shinichi Tamura, President and CEO of Sosei Heptares commented:"The results from the ARGON Phase IIIb study add to the extensive clinical data that Novartis has generated with once-daily IND/GLY/MF.

Key Points: 
  • Shinichi Tamura, President and CEO of Sosei Heptares commented:"The results from the ARGON Phase IIIb study add to the extensive clinical data that Novartis has generated with once-daily IND/GLY/MF.
  • These data show the potential of this novel combination product as an effective and convenient therapy in patients with uncontrolled asthma.
  • Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
  • Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.

Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma

Friday, June 5, 2020 - 8:18am

Shinichi Tamura, President and CEO of Sosei Heptares commented:"The results from the ARGON Phase IIIb study add to the extensive clinical data that Novartis has generated with once-daily IND/GLY/MF.

Key Points: 
  • Shinichi Tamura, President and CEO of Sosei Heptares commented:"The results from the ARGON Phase IIIb study add to the extensive clinical data that Novartis has generated with once-daily IND/GLY/MF.
  • These data show the potential of this novel combination product as an effective and convenient therapy in patients with uncontrolled asthma.
  • Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
  • Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.

Less Than One Year Post Launch, AbbVie's Rinvoq Disrupts the Rheumatoid Arthritis Treatment Landscape, While a Rich Pipeline Waits in the Wings

Friday, June 5, 2020 - 12:00am

Approved in 2012, Xeljanz enjoyed the "only JAK inhibitor" status for six years until Eli Lilly's Olumiant was approved.

Key Points: 
  • Approved in 2012, Xeljanz enjoyed the "only JAK inhibitor" status for six years until Eli Lilly's Olumiant was approved.
  • Where Olumiant faced challenges with regulatory delays and ultimately a less than desirable product label, Rinvoq came out of the gates strong.
  • AbbVie's SELECT-COMPARE trial, demonstrating Rinvoq's superiority over Humira, appears to be giving Rinvoq an advantage over existing JAK inhibitors, Xeljanz and Olumiant.
  • Indeed, this rich pipeline is poised to continue transforming the advanced systemic treatment landscape over the coming years.

Clinicians and scientists apply symptom tracking to COVID-19 outpatient care using famotidine

Thursday, June 4, 2020 - 11:30pm

This outpatient approach addresses the need to care for the majority of COVID-19 patients who do not require hospitalization.

Key Points: 
  • This outpatient approach addresses the need to care for the majority of COVID-19 patients who do not require hospitalization.
  • The first clinical case series showed that famotidine may help COVID-19 patients with mild to moderately severe symptoms.
  • Published in the journal GUT, the Northwell-CSHL case series is unique in adapting quantitative tracking of patient reported outcome measures.
  • A graded symptom score enables the physician and the patient to track symptoms using numbers."

ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis

Thursday, June 4, 2020 - 6:00am

The pilot study is a single-center, open-label study in women (n=9) with symptomatic adenomyosis confirmed by Magnetic Resonance Imaging (MRI).

Key Points: 
  • The pilot study is a single-center, open-label study in women (n=9) with symptomatic adenomyosis confirmed by Magnetic Resonance Imaging (MRI).
  • Patients are treated once daily with 200 mg linzagolix for 12 weeks, followed by 12 weeks of 100 mg linzagolix, both without hormonal add-back therapy (ABT).
  • The primary measure of efficacy is the reduction in uterine volume as measured by MRI.
  • ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for linzagolix.